Premature babies in the incubator, patients with acute lung failure in the intensive care unit or COPD patients at home: they all suffer from the same potentially fatal condition: hypercapnia = an increased level of CO₂ in the blood.

In Germany alone there are around 400,000 people a year!

Hypercapnia is one of the major challenges in the therapy of acute lung failure and long-term weaning in ICU and in the outpatient treatment of chronic obstructive pulmonary disease (COPD), which has not yet been adequately solved.

Our goal is to revolutionize therapy and significantly improve survival and, above all, the quality of life of these large patient groups suffering from hypercapnia.

Instead of tackling the problem through the lungs, RESPILIQ™ uses the human gut as a respiratory organ. The human intestine forms a highly effective exchange membrane for carbon dioxid (CO₂). In the gut, RESPILIQ™ can bind CO₂ from the intestinal fluid and excrete it via naturalis. Administered orally or rectally, RESPILIQ™ initiates a life-saving reduction of pCO₂ in the blood.